Medroxyprogesterone Acetate Injection, Suspension, Extended Release
Product Images NDC 0548-5701

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Medroxyprogesterone Acetate (NDC 0548-5701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amphastar Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton 5400

Box packaging label for MedroxyPROGESTERone Acetate Injectable Suspension USP 150 mg/mL by Amphastar Pharmaceuticals, Inc. The label indicates a 1 mL single-dose vial for intramuscular use only, with dosage strength clearly stated. It includes usage instructions, storage conditions, and the manufacturer’s information.*

FDA Label Image

Carton 5401

Medroxyprogesterone Acetate 150 mg/mL injection, suspension, extended release, intramuscular use. The label shows it is manufactured by Amphastar Pharmaceuticals, Inc. It is supplied in single-dose 1 mL vials. The packaging includes dosage and storage instructions and a list of inactive ingredients.*

FDA Label Image

Carton 5701

Medroxyprogesterone Acetate Injectable Suspension, USP 150 mg/mL carton label from Amphastar Pharmaceuticals, Inc. The label states it is for intramuscular use only and includes dosage and storage instructions. The label also lists the active ingredient strengths and assembly instructions for the packaging.*

FDA Label Image

Structure

Chemical structure diagram of Medroxyprogesterone acetate, showing its steroid backbone and functional groups.*

FDA Label Image

Chart

A vertical arrow chart illustrating pregnancy rates per 100 women in one year relative to birth control methods. The chart categorizes methods from fewer pregnancies (implants, injections, intrauterine devices, sterilization) to more pregnancies (no birth control), with intermediate categories including birth control pills, skin patches, vaginal rings, condoms, diaphragms, and behavior-based methods.*

FDA Label Image

Figure1and2

Two black-and-white line drawing illustrations demonstrating how to prepare a syringe with an extended-release injection suspension. Figure 1 shows the syringe being held and manipulated, and Figure 2 shows the syringe being positioned for administration.*

FDA Label Image

Risk Estimate

A forest plot chart showing risk estimates for breast cancer in users of Medroxyprogesterone Acetate (DMPA), displaying odds ratios with 95% confidence intervals on a logarithmic scale. The plot includes several studies comparing breast cancer risk, with values ranging approximately from 0.7 to 4.7, indicating varied risk estimates across studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.